Literature DB >> 6246848

Peripheral neuropathy after cis-platinum (II) (DDP) therapy.

L Reinstein, S S Ostrow, P H Wiernik.   

Abstract

A 56-year-old man developed a malignant fibrous histiocytoma in the left antecubital space in THE LEFT ANTECUBITAL SPACE IN September 1974. He underwent local resection, local radiation therapy, and chemotherapy with Adriamycin and Levamisole with resolution of the disease. In January 1977, a recurrent mass developed in the left antecubital space and electrophysiologic studies revealed segmental demyelination of the left median nerve across the tumor site. In July 1977, a Cis-diamminedichloplatinum (II) (DDP) therapy was instituted and 5 months later the patient developed paresthesias in both hands and both feet. Repeat nerve conduction studies revealed abnormalities in all 4 extremities consistent with a mixed sensorimotor peripheral neuropathy. Serial studies at 2-month intervals during DDP therapy showed further deterioration in nerve conduction. Following completion of DDP therapy, the patient's symptoms improved and subsequent nerve conduction studies done over an 11-month period showed improvement in nerve conduction with values approaching normal.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6246848

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  5 in total

1.  Severe sensorimotor neuropathy after cisplatin therapy.

Authors:  M Pagès; A M Pagès; L Bories-Azeau
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-03       Impact factor: 10.154

2.  Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy.

Authors:  H Shimizu; N Jaffe; E Kleinerman
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

3.  Cisplatin induces mitochondrial deficits in Drosophila larval segmental nerve.

Authors:  Jewel L Podratz; Han Lee; Patrizia Knorr; Stephanie Koehler; Steven Forsythe; Kelsey Lambrecht; Suzette Arias; Kiley Schmidt; Gabrielle Steinhoff; Georgiy Yudintsev; Amy Yang; Eugenia Trushina; Anthony Windebank
Journal:  Neurobiol Dis       Date:  2016-10-17       Impact factor: 5.996

4.  Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer.

Authors:  H I Scher; D Kelsen; L Kalman; L Jones; J Burchenal; R Gralla
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  In vitro antagonism between cisplatin and vinca alkaloids.

Authors:  K Lee; M Tanaka; H Kanamaru; T Hashimura; I Yamamoto; J Konishi; F Kuze
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.